Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Backseat drivers take the wheel.

P Andrew Futreal1

  • 1Cancer Genome Project, Wellcome Trust Sanger Institute, Hinxton CB10 1SA, UK. paf@sanger.ac.uk

Cancer Cell
|December 11, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Germline variants in cancer susceptibility genes among patients with mucosal melanoma.

NPJ genomic medicine·2026
Same author

Editor's Note: Analysis of Immune Signatures in Longitudinal Tumor Samples Yields Insight into Biomarkers of Response and Mechanisms of Resistance to Immune Checkpoint Blockade.

Cancer discovery·2025
Same author

Author Correction: Clonal evolution of hematopoietic stem cells after autologous stem cell transplantation.

Nature genetics·2025
Same author

Distinct Clinicogenomic Features and Immunotherapy Associations in Pulmonary Sarcomatoid Carcinoma: A Multicenter Retrospective Study.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer·2025
Same author

Clonal evolution of hematopoietic stem cells after autologous stem cell transplantation.

Nature genetics·2025
Same author

Oncogenic drivers shape the tumor microenvironment in human gliomas.

bioRxiv : the preprint server for biology·2025
Same journal

Vascular RhoJ Is an Effective and Selective Target for Tumor Angiogenesis and Vascular Disruption.

Cancer cell·2026
Same journal

Intratumoral B cells under stress.

Cancer cell·2026
Same journal

Chronic stress unleashes an intratumor phage-fibroblast-B cell circuit to promote tumor growth.

Cancer cell·2026
Same journal

Molecular phenotypes and spatial archetypes: A new framework for cancer-associated fibroblasts.

Cancer cell·2026
Same journal

OpenIO: An open framework for AI-native immunotherapy.

Cancer cell·2026
Same journal

From prediction to interpretation in computational pathology.

Cancer cell·2026
See all related articles

Identifying rare cancer-driving mutations is crucial. Researchers found new FLT3 mutations in acute myeloid leukemia, distinguishing drivers from passengers in patients lacking common mutations.

Area of Science:

  • Oncology
  • Genetics
  • Molecular Biology

Background:

  • Distinguishing cancer driver mutations from passenger mutations is a significant challenge in cancer research.
  • Driver mutations promote cancer growth, while passenger mutations are neutral byproducts of DNA damage.
  • FLT3 mutations are common in acute myeloid leukemia (AML), but rare drivers remain poorly understood.

Purpose of the Study:

  • To systematically identify rare driver mutations in the FLT3 gene in acute myeloid leukemia (AML).
  • To differentiate between driver and passenger mutations in FLT3, particularly in patients without common FLT3 alterations.
  • To functionally validate newly identified rare FLT3 mutations.

Main Methods:

  • Systematic resequencing of the FLT3 gene in a cohort of AML patients.

Related Experiment Videos

  • Functional validation assays to assess the oncogenic potential of identified mutations.
  • Bioinformatic analysis to distinguish driver from passenger mutations.

    • Main Results:

    • Identification of several rare, potentially driver mutations in FLT3.
    • Characterization of passenger mutations in FLT3 in AML patients.
    • Demonstration that these rare mutations can contribute to oncogenesis in a subset of AML patients negative for common FLT3 mutations.

    Conclusions:

    • The study successfully identified and validated rare FLT3 driver mutations in AML.
    • This research enhances our understanding of the genetic landscape of AML.
    • The findings may inform future diagnostic and therapeutic strategies for AML patients with rare FLT3 alterations.